TY - JOUR
T1 - Acquisition, prevalence and clearance of typespecific human papillomavirus infections in young sexually active Indian women
T2 - A community-based multicentric cohort study
AU - Indian HPV vaccine study group
AU - Muwonge, Richard
AU - Basu, Partha
AU - Gheit, Tarik
AU - Anantharaman, Devasena
AU - Verma, Yogesh
AU - Bhatla, Neerja
AU - Joshi, Smita
AU - Esmy, Pulikottil O.
AU - Poli, Usha Rani Reddy
AU - Shah, Anand
AU - Zomawia, Eric
AU - Shastri, Surendra S.
AU - Pimple, Sharmila
AU - Prabhu, Priya R.
AU - Hingmire, Sanjay
AU - Chiwate, Aruna
AU - Sauvaget, Catherine
AU - Lucas, Eric
AU - Malvi, Sylla G.
AU - Siddiqi, Maqsood
AU - Sankaran, Subha
AU - Kannan, Thiraviam Pillai Rameshwari Ammal
AU - Varghese, Rintu
AU - Divate, Uma
AU - Vashist, Shachi
AU - Mishra, Gauravi
AU - Jadhav, Radhika
AU - Tommasino, Massimo
AU - Pillai, M. Radhakrishna
AU - Sankaranarayanan, Rengaswamy
AU - Jayant, Kasturi
AU - Shah, Anand
AU - Esmy, Pulikottil O.
AU - Anilkumar, D.
AU - Kavitha, M.
AU - Umarani, P.
AU - Malvi, Sylla G.
AU - Jayant, Kasturi
AU - Hingmire, Sanjay
AU - Chiwate, Aruna
AU - Poli, Usha Rani Reddy
AU - Poojari, Renuka
AU - Varija, Y.
AU - Sujatha, M.
AU - Siddiqi, Maqsood
AU - Zomawia, Eric
AU - Mishra, Gauravi
AU - Bhatla, Neerja
AU - Vashist, Shachi
AU - Joshi, Smita
N1 - Funding Information:
This work was financially supported by The Bill & Melinda Gates Foundation (grant number OPP48979). Partial support was also obtained from the European Commission Seventh Framework Programme grant HPV-AHEAD (FP7- HEALTH-2011-282562) for the establishment of the Luminex-based assays at Rajiv Gandhi Centre for Biotechnology (RGCB), Trivandrum, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2020 Muwonge et al.
PY - 2020/12
Y1 - 2020/12
N2 - In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18-23 years were recruited in 2012-2015 as age-matched controls to the vaccinated women and followed up yearly. We assess type-specific prevalence, natural history and potential determinants of human papillomavirus (HPV) infection in these unvaccinated women. Cervical samples were collected yearly for at least four consecutive years. A Multiplex Type-Specific E7-Based polymerase chain reaction assay was used to detect 21 HPV types. HPV prevalence was 36.4% during 6 years. Most common HPV types were 16 (6.5%) and 31 (6.1%). Highest persistence were observed for HPV 35 (62.5%) and 52 (25%). New HPV acquisition rate was 5.6/1000 person-months of observation (PMO), highest for HPV 16 (1.1/1000 PMO). Type-specific clearance rates ranged between 2.9-5.5/100 PMO. HPV 16 and/or 18 infections were 41% (95% CI 4-63%) lower among women with 2-<3 years between marriage and first cervical sample collection compared to those with <2 years. HPV prevalence and acquisition rates in young Indian women were lower than their Western counterparts. HPV 16 infections being most common shows the importance and potential impact of HPV vaccination in India. Women with 2-3 years exposure had reduced risk possibly due to higher infections clearance.
AB - In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18-23 years were recruited in 2012-2015 as age-matched controls to the vaccinated women and followed up yearly. We assess type-specific prevalence, natural history and potential determinants of human papillomavirus (HPV) infection in these unvaccinated women. Cervical samples were collected yearly for at least four consecutive years. A Multiplex Type-Specific E7-Based polymerase chain reaction assay was used to detect 21 HPV types. HPV prevalence was 36.4% during 6 years. Most common HPV types were 16 (6.5%) and 31 (6.1%). Highest persistence were observed for HPV 35 (62.5%) and 52 (25%). New HPV acquisition rate was 5.6/1000 person-months of observation (PMO), highest for HPV 16 (1.1/1000 PMO). Type-specific clearance rates ranged between 2.9-5.5/100 PMO. HPV 16 and/or 18 infections were 41% (95% CI 4-63%) lower among women with 2-<3 years between marriage and first cervical sample collection compared to those with <2 years. HPV prevalence and acquisition rates in young Indian women were lower than their Western counterparts. HPV 16 infections being most common shows the importance and potential impact of HPV vaccination in India. Women with 2-3 years exposure had reduced risk possibly due to higher infections clearance.
UR - http://www.scopus.com/inward/record.url?scp=85098986822&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098986822&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0244242
DO - 10.1371/journal.pone.0244242
M3 - Article
C2 - 33373380
AN - SCOPUS:85098986822
SN - 1932-6203
VL - 15
JO - PloS one
JF - PloS one
IS - 12
M1 - e0244242
ER -